[{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":1.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":1.25,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi ","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi "},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.34999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.40000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"OrphanDC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRIA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pint Pharma \/ OrphanDC","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ OrphanDC"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Enable Injections","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Enable Injections","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Enable Injections \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Enable Injections \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals"}]
Find Clinical Drug Pipeline Developments & Deals for Pegcetacoplan
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
